Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (276 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-04-10. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patienthoursfailureintravenouspurpose of
  Phrases that lowered it: the efficacymildevaluate themoderatehealth
• Sponsor's past termination rate: 14.6% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past trials: 903 (raises risk) · Sponsor's track record
• Blinding: triple (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 13.4% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 90.8% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 270 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 83281 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 6877 (lowers risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine NCT03061734 · started 2017 · scored riskier than 19% of active trials completed
• An Acute Migraine Factorial Study NCT06245902 · started 2017 · scored riskier than 18% of active trials completed
• Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg Vs Placebo As Adjuvant Treatment in Chronic Migraine - NCT04989413 · started 2022 · scored riskier than 14% of active trials terminated
• A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine NCT04152083 · started 2019 · scored riskier than 22% of active trials completed
• A Study of LY2951742 in Participants With Migraine NCT01625988 · started 2012 · scored riskier than 53% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.